# ASPEN AEROGELS INC (ASPN) — Financial Analysis **Exchange:** NYSE **Coverage as of:** 2026-Q2 **Updated:** 2026-06-17 **Tier:** Free primer (step 2 of 19) **Sibling pages:** /stocks/aspn/thesis · /memo/aspn ## Financial Snapshot --- source: coverage-next-full ticker: ASPN step: 04 title: Financial Quality & Adversarial Research Sweep date: 2026-06-17 --- ### Step 04 — Financial Quality & Adversarial Research Sweep #### Aspen Aerogels, Inc. (NYSE: ASPN) --- #### 1. Executive Summary Aspen Aerogels presents one of the more complex financial quality cases in small-cap industrials: a genuine product and technology (PyroThin aerogel thermal barriers for EV battery packs) that attracted real customer adoption, followed by an over-leveraged capacity build for a single customer whose volumes collapsed. The FY2025 GAAP income statement is nearly unintelligible without normalization — a $389.6M net loss on $271M of revenue reflects $291.2M in non-cash Statesboro impairment charges plus associated restructuring. Stripped of those one-time items, the normalized picture is painful but survivable: approximately -$65M net loss on revenues that fell 40% year-over-year as GM dramatically curtailed EV production. Key financial quality concerns: (1) the Statesboro write-off crystallizes ~$300M of value destruction from a "build-for-one-customer" capacity bet that was entirely rational in 2022 but proved catastrophically wrong; (2) the MidCap credit facility was amended twice in 2025, including removal of the EBITDA covenant in December 2025, signaling meaningful lender accommodation; (3) the April 8, 2026 explosion at East Providence — ASPN's sole remaining manufacturing facility — created a force-majeure supply disruption that rendered Q1 2026 revenue ($37.9M) essentially a floor print; (4) CFO Ricardo Rodriguez departed October 2025 after insider selling near the stock's peak. On balance, this is a financially stressed but not fatally broken company: $157M+ cash, net cash position, insurance coverage for the plant disruption, and a meaningful $37.6M GM commercial settlement received in Q1 2026 provide a credible 12–18 month liquidity runway. The financial quality score is 4/10 — below average due to single-customer concentration risk that materialized, aggressive capex that was subsequently written off, management credibility concerns, and ongoing plant disruption risk. --- #### 2. Statement Quality Adjustments ##### FY2025 Normalization The reported FY2025 financials require substantial adjustments to understand recurring economics [S1]: | Item | Reported | Adjustment | Normalized | |------|----------|-----------|-----------| | Revenue | $271.1M | — | $271.1M | | Gross Profit | $42M | — | $42M | | Gross Margin | 15% | — | 15% | | Operating Income | -$330M | +$291.2M impairment; +~$9M restructuring/demobilization | ~-$30M | | Net Income | -$389.6M | +$291.2M impairment + restructuring + tax effects | ~-$65M | The $291.2M impairment charge consists of $286.6M in long-lived asset impairment for the Statesboro facility plus approximately $4.6M in additional losses on assets held for sale [S2]. These are genuine economic losses — the cash was already spent in FY2022–FY2023 capex — but they are non-recurring items that inflate the reported loss by 4.5× and obscure the underlying operating trend. Restructuring and accelerated depreciation added approximately $9–10M in additional charges. Excluding all Statesboro-related items, normalized operating loss was approximately -$30M to -$35M on $271M revenue — a normalized operating margin of roughly -12%, worsening from FY2024's +12% as GM volumes collapsed. ##### FY2024: The Peak Year FY2024 ($453M revenue, 40% gross margin, +$55M operating income) represented ASPN's first-ever year of GAAP operating profitability and remains the reference point for the bull case. Revenue grew 90% year-over-year, driven almost entirely by PyroThin shipments to GM's Ultium platform. The quality of FY2024 earnings is moderate: the gross margin expansion from 32% (FY2023) to 40% was real operating leverage, but the concentration risk was also at its highest point — GM represented approximately 64% of FY2024 revenue [S3]. ##### FY2023: Investment Trough FY2023 gross margins of 32% (up from 18% in FY2022) reflected genuine mix improvement as PyroThin scaled. The -$16M operating loss was largely capex-cycle related (high D&A from Statesboro construction-in-progress, partly offset by improving gross profits). Revenue recognition is straightforward — physical shipments of manufactured product — reducing the risk of aggressive accrual accounting. --- #### 3. Cash Flow Quality ##### OCF vs. Net Income Reconciliation The divergence between OCF and net income in FY2025 is extreme but explainable [S1]: | Year | Net Income | Operating CF | Delta | Primary Driver | |------|-----------|-------------|-------|----------------| | FY2021 | -$53M | -$27M | +$26M | D&A add-back | | FY2022 | -$70M | -$57M | +$13M | D&A + modest WC | | FY2023 | -$41M | -$40M | +$1M | Roughly matched | | FY2024 | +$13M | +$51M | +$38M | WC release + D&A | | FY2025 | -$390M | +$20M | +$410M | $291M impairment add-back + WC | The massive FY2025 OCF/net income gap is almost entirely explained by the non-cash $291.2M impairment charge being added back in the cash flow reconciliation — this is accounting mechanics, not a quality concern in isolation. However, the more important signal is that FY2025 OCF was only +$20M despite $410M of non-cash add-backs suggesting a working capital drag of approximately $100M+ as revenues collapsed. This likely reflects inventory build (Statesboro-related materials), receivables normalization timing, and restructuring cash costs. The TTM OCF of approximately +$36M (including Q1 2026's +$34.1M, boosted materially by the $37.6M GM settlement received in cash) is optically better than the run-rate underlying business. Excluding the one-time GM settlement, Q1 2026 OCF would likely have been close to breakeven or negative, consistent with the -$12.7M Adjusted EBITDA reported for the quarter [S4]. ##### Capex Cycle Analysis The capex profile tells the story of the strategic bet and its reversal: - FY2022: -$272M capex — Statesboro Phase 1 construction - FY2023: -$218M capex — Statesboro completion + East Providence upgrade - FY2024: -$100M capex — tapering; focus on operationalizing capacity - FY2025: -$25M capex — hard pivot; Statesboro abandoned - FY2026 guidance: maintenance-level capex, sub-$20M expected The cumulative capex of approximately $700M over FY2021–FY2025 against cumulative OCF of roughly -$53M implies ASPN consumed approximately $750M+ in total capital over this period. The equity raises and debt that funded this are the primary source of the dilution and leverage discussed in sections 5 and 4 respectively. ##### Working Capital Dynamics As revenue collapsed from $453M (FY2024) to $271M (FY2025), one would expect accounts receivable to have declined proportionately. The absence of a large receivables release in FY2025 OCF (it was only +$20M despite $291M+ in non-cash items) suggests either (a) inventory built up as Statesboro wound down, (b) some stretching of collections, or (c) timing of cash receipts across the year-end. The $37.6M GM commercial settlement received in Q1 2026 partially clarifies this picture — it was a retrospective negotiation on contract terms, and its receipt in March 2026 boosted Q1 2026 OCF to +$34.1M [S4]. The underlying Q1 2026 business without this settlement was cash-consuming. --- #### 4. Balance Sheet Analysis ##### Asset Quality Post-Statesboro write-off, the balance sheet has been substantially cleansed of inflated PP&E [S1]: - **FY2025 total assets: $407M** (down from ~$895M pre-impairment) - **Cash & equivalents: $156.9M** (FY2025 year-end); rose to $173.9M by Q1 2026 end - **PP&E (net): ~$120–130M** — primarily the East Providence facility - **Goodwill/intangibles: minimal** — ASPN is a single-site manufacturer - **Inventory: moderate** — aerogel rolls and thermal barrier components The primary asset quality risk now is the East Providence facility itself. The April 8, 2026 explosion rendered ASPN's sole production facility offline at a time when the company is already in a fragile revenue recovery. Insurance claims have been filed (property damage and business interruption) and the company expects a staged restart beginning May 2026 [S5]. A prolonged outage beyond 60–90 days would materially strain the balance sheet despite the cash cushion. ##### Debt Structure and Covenant Risk **MidCap Financial credit facility** (as amended December 2025) [S6]: - Term loan balance: $86.0M (Q1 2026) - Revolving credit: $7.1M drawn; additional availability provides liquidity buffer - EBITDA covenant: **removed entirely** in December 2025 amendment - Minimum liquidity covenant: raised to 100% of outstanding term loan principal (~$86M) - Compliance as of March 31, 2026: confirmed The removal of the EBITDA covenant is the most significant red flag on the balance sheet. Lenders do not remove financial maintenance covenants for healthy borrowers — they do it to avoid triggering a technical default when they believe a company is in genuine but temporary distress. The fact that MidCap accommodated two amendments in 2025 (May and December) rather than accelerating the debt suggests they view ASPN as a recoverable credit, but the accommodation itself confirms the company was covenant-stressed throughout FY2025. With $173.9M cash vs. $93.1M total debt (term + revolver) as of Q1 2026 end, net cash position is approximately +$80M — meaning the debt is manageable if the business stabilizes, but a further revenue deterioration or prolonged plant outage would erode this cushion quickly. Net debt-to-normalized EBITDA is not calculable in a meaningful way given negative EBITDA on a trailing basis. On a forward basis, if ASPN achieves its H2 2026 EBITDA breakeven target at $50M/quarter revenue, leverage would be approaching zero on an annualized basis. --- #### 5. SBC & Dilution Analysis Stock-based compensation at ASPN has been persistently elevated relative to company size [S3]: | Year | Approx. SBC | Revenue | SBC as % Revenue | |------|------------|---------|-----------------| | FY2021 | ~$10M | $104M | ~10% | | FY2022 | ~$18M | $145M | ~12% | | FY2023 | ~$22M | $238M | ~9% | | FY2024 | ~$28M | $453M | ~6% | | FY2025 | ~$10M (H2 run-rate $5M/half) | $271M | ~4% | SBC as a percentage of revenue has improved significantly as ASPN scaled revenue and then cut compensation costs in the restructuring. The 2025 restructuring appears to have meaningfully reduced the SBC burden, with H2 2025 guidance of approximately $5M/half ($10M annualized) — down from peak levels. This is a positive trend. **Dilution:** Basic shares outstanding grew from approximately 50M (FY2020) to 82.9M (FY2025) — a 66% increase over five years, implying roughly 10–11% annualized dilution from equity issuances and SBC exercises [S7]. The majority of dilution came from capital raises in FY2021–FY2022 to fund Statesboro construction, not ongoing SBC. However, the equity raises at prices far above current levels (~$30–$50/share range during the buildout vs. current single-digit prices) means that dilution destroyed substantial per-share value. The insider selling incident — former CFO Ricardo Rodriguez sold approximately $978K of stock at roughly $30/share in August 2024 shortly before the stock collapsed to single digits — is discussed in Section 6 below. --- #### 6. Adversarial Research Sweep ##### 6a. Short Seller Reports and Bearish Theses No formal short seller report (Hindenburg, Citron, Muddy Waters style) was identified for ASPN in searches through June 2026 [S8]. The absence of a formal short report is notable — ASPN's concentrated customer exposure, aggressive capex, and subsequent impairment would typically attract short-seller attention. The most likely explanation is that the stock's ~85% decline from peak ($30+ in 2024 to ~$3–5 in early 2026) occurred through fundamental deterioration rather than an externally exposed fraud. The bearish consensus among sell-side analysts centers on: (1) GM EV production resets to approximately 176,000 Ultium-platform vehicles in 2026 vs. prior peak expectations, (2) solid-state battery technology as a long-term demand threat (if successful, eliminates the need for thermal barrier insulation), and (3) customer concentration that structurally limits pricing power. Multiple analysts have cut price targets to the $3–6 range. Short interest as tracked by Fintel has been meaningful but not extraordinary, consistent with a value-deterioration short thesis rather than a fraud thesis [S8]. ##### 6b. Litigation and Regulatory Issues Material litigation as of the most recent filings is limited [S1][S9]: - **AMA Patent Dispute (Italy):** Aspen settled its patent infringement action against AMA S.p.A. and AMA Composites S.r.l. in January 2025. AMA had allegedly sold infringing aerogel insulation in Europe. Settlement terms were not disclosed publicly but the case is closed. - **GM Commercial Settlement ($37.6M):** Received in Q1 2026. This is the most significant financial litigation-adjacent event — it suggests a disputed contract claim (likely related to volume shortfalls vs. contractual commitments) that Aspen pursued successfully. The settlement is recognized over approximately two years (deferred revenue treatment), reducing the cash-to-revenue recognition mismatch risk. - **East Providence Regulatory/Safety Investigations:** The April 8, 2026 explosion is subject to investigation by local, state, and federal agencies (OSHA at minimum). No OSHA citations or enforcement actions have been publicly reported as of June 2026. Eleven employees required medical evaluation; all were reportedly released. Potential liability exposure from worker injuries or property damage beyond insurance limits is a tail risk [S5]. - **No SEC investigation or restatement identified:** SEC EDGAR searches show no comment letters with material accounting disputes and no restatements in the public record. ##### 6c. Accounting Red Flags Several items warrant scrutiny but do not rise to the level of fraud indicators: 1. **Statesboro Impairment Timing:** The $291.2M impairment was recorded in Q1 2025. Questions arise about whether the write-down should have come sooner — by mid-2024, GM's EV production revisions were becoming public. Had Aspen tested the long-lived assets more aggressively during FY2024, an impairment could arguably have been triggered then. However, impairment testing requires demonstrating that carrying value exceeds fair value using a probability-weighted future cash flow model, and the asset technically had ongoing utility as long as a customer relationship existed. The timing does not appear to constitute an accounting irregularity, though it was at the outer edge of defensible. 2. **Revenue Recognition:** PyroThin revenue is recognized on physical shipment (point-in-time), reducing accrual gaming risk. The $37.6M GM settlement's two-year deferred recognition is appropriate under ASC 606 (it represents a contract modification with future performance obligations). No evidence of pull-forward revenue recognition was identified. 3. **Capitalized Costs:** Statesboro construction costs were appropriately capitalized as PP&E under GAAP. The retrospective question is whether the investment decision was sound — it was not — but the accounting treatment was correct. 4. **D&A and PP&E Life Assumptions:** Post-Statesboro, D&A will decline sharply as the written-off assets leave the depreciation schedule. This will mechanically improve reported earnings in FY2026 regardless of operational performance. Investors should be aware that this "accounting tailwind" is an artifact of the write-off, not operational improvement. ##### 6d. Management Credibility Issues Two events raise management credibility concerns: **CFO Departure (October 2025):** Ricardo Rodriguez joined ASPN in November 2021 as Chief Strategy Officer and was appointed CFO in April 2022 — during the peak of the Statesboro buildout. He departed in October 2025, concurrent with the Q3 2025 earnings release, replaced by an internal successor, Grant Thoele. The departure timing — after the impairment was booked but while the company is in restructuring — is consistent with a board-initiated change rather than voluntary resignation. The internal succession (rather than an external hire) somewhat reduces concern about a "clean house" scenario. Nonetheless, Rodriguez oversaw the financial planning and capital structure decisions that accompanied the aggressive Statesboro buildout, and his departure at this juncture is not confidence-inspiring [S9]. **Insider Selling at Peak:** Former CFO Rodriguez sold approximately $978K of ASPN stock at approximately $30/share in August 2024. The stock subsequently declined approximately 85% to the $4–5 range by early 2026. While $978K is not a massive sum relative to total company market cap, the timing — selling near the stock's all-time high, roughly 6–8 months before the company would disclose Statesboro impairment — raises questions. Sales under a pre-arranged 10b5-1 plan would reduce (though not eliminate) the inference of information asymmetry. SEC Form 4 filings show the transaction but available search results do not confirm whether a 10b5-1 plan was in place [S10]. This remains an open adversarial question. ##### 6e. Customer Concentration Risk — What Actually Happened with GM The GM concentration story is the central financial quality failure at ASPN: - **Peak concentration (FY2024):** GM represented approximately 64% of total revenue (~$290M of $453M), almost entirely through PyroThin thermal barrier shipments for Ultium-platform vehicles (Chevrolet Silverado EV, Blazer EV, Equinox EV, GMC Sierra EV, Hummer EV) - **The collapse:** GM significantly revised its EV production targets in late 2024 and into 2025 as consumer EV adoption lagged expectations. GM's Ultium platform vehicles saw slower sales than anticipated, and GM deferred several planned EV model introductions. For ASPN, this meant PyroThin revenue fell from $306.8M (FY2024) to approximately $168.9M (FY2025) — a 45% decline in one product line from one customer [S3] - **Statesboro was built to serve GM:** The $490M+ in total Statesboro-related capex was premised on GM requiring a second aerogel plant to meet Ultium production targets. When GM's EV production plans reset, the asset had no alternative use case at scale. The $291.2M impairment follows directly - **Q1 2026 GM revenue ($16.3M thermal barrier):** Annualizes to roughly $65M — approximately 22% of FY2024 peak levels. GM's 2026 EV production forecast of ~176,000 Ultium vehicles (up 25% from 2025's depressed levels) suggests some recovery, but the concentration risk remains - **European pivot:** ASPN has announced wins with unspecified European OEMs for PyroThin supply, which management cites as the primary diversification strategy. No revenue impact has yet been disclosed; the geographic pivot is a medium-term story at best ##### 6f. SEC Comment Letters and Restatements No evidence of SEC comment letter exchanges raising material accounting concerns was identified in searches through June 2026. No financial restatements appear in the public record. The FY2025 10-K was filed on the standard schedule without extension, and there is a subsequent 10-K/A amendment noted in SEC EDGAR [S1], though the nature of the amendment (likely immaterial technical corrections) is not detailed in available sources. --- #### 7. Financial Quality Score **Score: 4 / 10** | Dimension | Sub-Score | Commentary | |-----------|-----------|-----------| | Revenue Quality | 5/10 | Point-in-time product revenue is clean; concentration is the defect | | Earnings Quality | 4/10 | Heavy non-cash items; normalized losses still material; SBC declining | | Cash Flow Quality | 5/10 | OCF has been positive recently, but GM settlement distorts Q1 2026; underlying FCF negative for 5 straight years | | Balance Sheet Quality | 4/10 | Net cash positive but achieved through equity dilution; Statesboro write-off crystallizes capital destruction; covenant amendments signal prior stress | | Management Credibility | 3/10 | CFO departure, peak-timing insider sales, aggressive capital misallocation — not fraud indicators but all net negatives | | Governance/Litigation | 6/10 | No SEC investigations, no restatements, limited active litigation; patent case settled; plant explosion under investigation | **Overall: 4/10.** Below-average financial quality. The company operates a real business with genuine product-market fit, but has demonstrated poor capital allocation discipline (Statesboro), dangerous single-customer concentration, and questionable management actions around the stock's peak. The balance sheet is stabilizing post-impairment, and the absence of accounting fraud or restatements provides a floor. The score would improve toward 6/10 if: (a) East Providence restarts without further incident, (b) European OEM revenue diversifies the customer base, and (c) management demonstrates EBITDA breakeven by H2 2026 as guided. --- #### 8. Source Index - [S1] Aspen Aerogels FY2025 10-K (Annual Report) — SEC EDGAR, ASPN (CIK 0001145986) - [S2] Aspen Aerogels Q1 2025 Earnings Release (8-K) — SEC EDGAR; Statesboro impairment $286.6M + $4.6M loss on assets held for sale - [S3] Aspen Aerogels FY2024 10-K — GM customer concentration (64% of revenue), PyroThin revenue breakdown - [S4] Aspen Aerogels Q1 2026 10-Q — SEC EDGAR (filed May 8, 2026); cash $173.9M, OCF +$34.1M, GM settlement $37.6M deferred, MidCap covenant compliance - [S5] Aspen Aerogels East Providence Facility Update — GlobeNewswire, April 21, 2026; staged restart May 2026; insurance claims initiated - [S6] Aspen Aerogels MidCap Credit Facility Amendment Announcement — GlobeNewswire, December 17, 2025; EBITDA covenant removed, liquidity covenant revised - [S7] Aspen Aerogels Shares Outstanding Historical Data — MacroTrends ASPN; ~50M to ~82.9M shares FY2020–FY2025 - [S8] Fintel.io ASPN Short Interest Data; web searches for Hindenburg/Citron/Muddy Waters ASPN reports — no formal short report identified as of June 2026 - [S9] Aspen Aerogels Q2 2025 Earnings Release (8-K) — CFO transition announcement; Rodriguez departure October 2025, Thoele successor - [S10] SEC Form 4 Filings — Ricardo Rodriguez insider sales August 2024; GuruFocus insider trading records; 10b5-1 plan status unconfirmed in available sources - [S11] Aspen Aerogels AMA Patent Settlement Press Release — PR Newswire, January 2025; Italian patent dispute resolved --- *Step 04 of 20 | Coverage-Next-Full | No earnings transcripts — sources: 10-K/10-Q/8-K MD&A, press releases, SEC filings, web search* ## Deeper Financial Analysis The fundamental tier ($1.00) adds 8 dimensions not included here: - Revenue Breakdown — segment revenue, geographic mix, product-line margins - Financial Trends — QoQ momentum, leading indicators, inflection points - Balance Sheet — debt structure, dilution risk, working capital dynamics - Capital Allocation — ROIC, buyback cadence, reinvestment efficiency - Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights - Competitive Positioning — market share, pricing power, peer benchmarks - Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop **API endpoint:** GET /api/v1/research/ASPN/fundamental ## Navigation - Overview: /stocks/aspn - Financials (this page): /stocks/aspn/financials - Thesis: /stocks/aspn/thesis - Investment Memo: /memo/aspn - Coverage universe: /stocks